<VariationArchive VariationID="43601" VariationName="NM_000551.4(VHL):c.408del (p.Phe136fs)" VariationType="Deletion" Accession="VCV000043601" Version="8" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-03-11" DateCreated="2018-04-09" MostRecentSubmission="2022-07-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="52770" VariationID="43601">
      <GeneList>
        <Gene Symbol="LOC107303340" FullName="3p25 von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase Alu-mediated recombination region" GeneID="107303340" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10142339" stop="10160352" display_start="10142339" display_stop="10160352" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="VHL" FullName="von Hippel-Lindau tumor suppressor" GeneID="7428" HGNC_ID="HGNC:12687" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10141778" stop="10153667" display_start="10141778" display_stop="10153667" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10183318" stop="10195353" display_start="10183318" display_stop="10195353" Strand="+" />
          </Location>
          <OMIM>608537</OMIM>
          <Haploinsufficiency last_evaluated="2022-05-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=VHL">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-05-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=VHL">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000551.4(VHL):c.408del (p.Phe136fs)</Name>
      <CanonicalSPDI>NC_000003.12:10146578:TTT:TT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3p25.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10146579" stop="10146579" display_start="10146579" display_stop="10146579" variantLength="1" positionVCF="10146578" referenceAlleleVCF="AT" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10188263" stop="10188263" display_start="10188263" display_stop="10188263" variantLength="1" positionVCF="10188262" referenceAlleleVCF="AT" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>F136fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_322" sequenceAccession="LRG_322">
            <Expression>LRG_322:g.9947del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000551.3" sequenceAccession="NM_000551" sequenceVersion="3" change="c.408delT">
            <Expression>NM_000551.3:c.408delT</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.10188265del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.10188265del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.10146581del" Assembly="GRCh38">
            <Expression>NC_000003.12:g.10146581del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008212.3" sequenceAccession="NG_008212" sequenceVersion="3" change="g.9947del">
            <Expression>NG_008212.3:g.9947del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_046756.1" sequenceAccession="NG_046756" sequenceVersion="1" change="g.4343del">
            <Expression>NG_046756.1:g.4343del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000551.4" sequenceAccession="NM_000551" sequenceVersion="4" change="c.408del" MANESelect="true">
            <Expression>NM_000551.4:c.408del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000542.1" sequenceAccession="NP_000542" sequenceVersion="1" change="p.Phe136fs">
            <Expression>NP_000542.1:p.Phe136fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001354723.2" sequenceAccession="NM_001354723" sequenceVersion="2" change="c.*18-3206del">
            <Expression>NM_001354723.2:c.*18-3206del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_198156.3" sequenceAccession="NM_198156" sequenceVersion="3" change="c.341-3206del">
            <Expression>NM_198156.3:c.341-3206del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA020343" DB="ClinGen" />
        <XRef Type="rs" ID="397516442" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000551.4(VHL):c.408del (p.Phe136fs) AND Von Hippel-Lindau syndrome" Accession="RCV000036544" Version="9">
        <ClassifiedConditionList TraitSetID="570">
          <ClassifiedCondition DB="MedGen" ID="C0019562">Von Hippel-Lindau syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-05-25" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000551.4(VHL):c.408del (p.Phe136fs) AND not provided" Accession="RCV000679039" Version="5">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2016-11-22" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-05-25" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2018-04-09" MostRecentSubmission="2022-07-17">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10340905</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15177666</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15932632</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16488999</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21389259</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29437867</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29748190</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31368132</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="570" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6116" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Von Hippel-Lindau</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Von Hippel-Lindau syndrome</ElementValue>
                <XRef ID="Von+Hippel-Lindau+syndrome/7416" DB="Genetic Alliance" />
                <XRef ID="46659004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">VHL syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">VHLS</ElementValue>
                <XRef Type="MIM" ID="193300" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Von Hippel-Lindau (VHL) syndrome is characterized by hemangioblastomas of the brain, spinal cord, and retina; renal cysts and clear cell renal cell carcinoma; pheochromocytoma, pancreatic cysts, and neuroendocrine tumors; endolymphatic sac tumors; and epididymal and broad ligament cysts. Cerebellar hemangioblastomas may be associated with headache, vomiting, gait disturbances, or ataxia. Spinal hemangioblastomas and related syrinx usually present with pain. Sensory and motor loss may develop with cord compression. Retinal hemangioblastomas may be the initial manifestation of VHL syndrome and can cause vision loss. Renal cell carcinoma occurs in about 70% of individuals with VHL and is the leading cause of mortality. Pheochromocytomas can be asymptomatic but may cause sustained or episodic hypertension. Pancreatic lesions often remain asymptomatic and rarely cause endocrine or exocrine insufficiency. Endolymphatic sac tumors can cause hearing loss of varying severity, which can be a presenting symptom. Cystadenomas of the epididymis are relatively common. They rarely cause problems, unless bilateral, in which case they may result in infertility.</Attribute>
                <XRef ID="NBK1463" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7855" />
                <XRef ID="7855" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000552165" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000553527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569658" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562500" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528276" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569525" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000553528" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000314230" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301636</ID>
                <ID Source="BookShelf">NBK1463</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Renal cell carcinoma genetics">
                <ID Source="PubMed">26389510</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Von Hippel-Lindau">
                <URL>https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics/vhl-syndrome</URL>
                <CitationText>PDQÂ® Cancer Genetics Editorial Board. PDQ Von Hippel-Lindau Disease. Bethesda, MD: National Cancer Institute. Updated &lt;03/08/2021&gt;. Accessed &lt;05/05/2021&gt;.</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <XRef ID="892" DB="Orphanet" />
              <XRef ID="C0019562" DB="MedGen" />
              <XRef ID="MONDO:0008667" DB="MONDO" />
              <XRef Type="MIM" ID="193300" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4987283" SubmissionDate="2022-07-15" DateLastUpdated="2022-07-17" DateCreated="2022-07-17">
        <ClinVarSubmissionID localKey="NM_000551.3:c.408delT|MedGen:C0019562" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002548087" DateUpdated="2022-07-17" DateCreated="2022-07-17" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16488999</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21389259</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29437867</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29748190</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31368132</ID>
          </Citation>
          <Comment>Variant summary: VHL c.408delT (p.Phe136LeufsX23) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251496 control chromosomes (gnomAD). c.408delT has been reported in the literature in multiple individuals affected with Von Hippel-Lindau Syndrome (e.g. Banks_2006, Krauss_2018, Aronoff_2018). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="VHL" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000551.3:c.408delT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0019562" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11800792</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1570228" SubmissionDate="2018-01-29" DateLastUpdated="2018-09-14" DateCreated="2018-09-14">
        <ClinVarSubmissionID localKey="NM_000551.3:c.408delT|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000805347" DateUpdated="2018-09-14" DateCreated="2018-09-14" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" OrgAbbreviation="PG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-11-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000551.3:c.408delT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB3589995</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="101399" SubmissionDate="2019-03-21" DateLastUpdated="2019-08-26" DateCreated="2013-05-03">
        <ClinVarSubmissionID localKey="21790900|Orphanet:ORPHA892" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000060199" DateUpdated="2019-08-26" DateCreated="2013-05-03" Type="SCV" Version="6" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-02-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10340905</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15932632</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21389259</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16488999</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15177666</ID>
          </Citation>
          <Comment>The p.Phe136fs variant in VHL has been reported as a somatic change occurring in renal cell carcinoma (Brauch 1999, Brauch 2004, Houweligen 2005, Banks 2006, Fo rmenti 2011). It has also been identified by our laboratory as a heterozygous g ermline variant in 1 individual with VHL and segregated with disease in 1 affect ed relative, although 1 obligate carrier was apparently unaffected. This framesh ift variant is predicted to alter the protein?s amino acid sequence beginning at position 136 and lead to a premature termination codon 23 amino acids downstrea m. This alteration is then predicted to lead to a truncated or absent protein. H eterozygous loss of function of the VHL gene is an established disease mechanism in VHL. In summary, this variant meets our criteria to be classified as pathoge nic for autosomal dominant VHL.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LMM Criteria</Attribute>
          <Citation>
            <ID Source="PubMed">24033266</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not provided</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="1" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="5" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="VHL" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000551.3:EXON 2</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>NM_000551.3:c.408delT</Name>
            <Name>p.Phe136fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.10188265delT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA892" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5348979</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="101399" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA892" MappingRef="Orphanet">
        <MedGen CUI="C0019562" Name="Von Hippel-Lindau syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1570228" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4987283" TraitType="Disease" MappingType="XRef" MappingValue="C0019562" MappingRef="MedGen">
        <MedGen CUI="C0019562" Name="Von Hippel-Lindau syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

